Please login to the form below

Not currently logged in
Email:
Password:

Watson launches generic Lipitor in Canada

Watson Pharmaceuticals' subsidiary, Cobalt Pharmaceuticals, is to market a generic version of Pfizer's Lipitor in Canada

Watson Pharmaceuticals has announced that its subsidiary, Cobalt Pharmaceuticals, is to market a generic version of Pfizer's statin, Lipitor (atorvastatin calcium) in Canada. 

The announcement follows Cobalt Pharmaceuticals receiving a Notice of Compliance from Health Canada to market atorvastatin calcium tablets in 10, 20, 40 and 80 mg strengths.

"We are very pleased that our Cobalt organisation will be adding this important therapy to its expanding portfolio of products," said Paul Bisaro, president and CEO of Watson Pharmaceuticals.

"Cobalt is well positioned to maximise the launch of the largest product to be offered as a generic in the history of the Canadian generic pharmaceutical industry," he continued.

Atorvastatin calcium is indicated to reduce the risk of heart attack, stroke, certain kinds of heart surgeries and chest pain in patients with either heart disease or several common risk factors for heart disease.

According to IMS Health, Lipitor had total Canadian sales of around $1bn for the year ending March 2010.

20th May 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics